Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials

Table 2

a: Leave-one-out sensitivity analysis for GMIs (ertugliflozin vs. control). b: Sensitivity analysis by excluding two studies that were not placebo-controlled.

Study excluded	RR (95% CI)	-test value	Heterogeneity ()
a
15 mg vs. control 26 weeks
Dagogo-Jack (2018) [19]	4.42 (1.96, 10.00)		; %
Ji (2019) [14]	5.98 (2.84, 12.56)		; %
Pratley (2018) [17]	4.34 (1.99, 9.47)		; %
Rosenstock (2018) [6]	4.62 (1.93, 11.03)		; %
Terra (2017) [21]	6.39 (2.12, 19.27)		; %
5 mg vs. control 26 weeks
Dagogo-Jack (2018) [19]	3.67 (1.73, 7.77)		; %
Ji (2019) [14]	4.74 (2.21, 10.15)		; %
Pratley (2018) [17]	3.55 (1.70, 7.42)		; %
Rosenstock (2018) [6]	3.77 (1.73, 8.26)		; %
Terra (2017) [21]	5.93 (2.25, 15.58)		; %
15 mg vs. control 52 weeks
Aronson (2018) [20]	9.32 (4.03, 21.52)		; %
Dagogo-Jack (2018) [19]	5.24 (2.44, 11.27)		; %
Hollander (2018) [18]	4.73 (2.14, 10.44)		; %
Pratley (2018) [17]	5.82 (2.27, 14.93)		; %
5 mg vs. control 52 weeks
Aronson (2018) [20]	8.66 (3.74, 20.06)		; %
Dagogo-Jack (2018) [19]	4.73 (2.00, 11.16)		; %
Hollander (2018) [18]	4.51 (1.74, 11.70)		; %
Pratley (2018) [17]	5.35 (1.85, 15.42)		; %
15 mg vs. control 104 weeks
Gallo (2019) [16]	11.67 (3.62, 37.65)		NA
Hollander (2019) [15]	5.44 (1.61, 18.38)		NA
5 mg vs. control 104 weeks
Gallo (2019) [16]	10.43 (3.22, 33.80)		NA
Hollander (2019) [15]	4.38 (1.27, 15.13)		NA
b
15 mg vs. control 52 weeks
Hollander (2018) [18]; Pratley (2018) [17]	4.73 (1.29, 17.39)		; %
5 mg vs. control 52 weeks
Hollander (2018) [18]; Pratley (2018) [17]	4.41 (0.94, 20.64)		; %

RR: risk ratio; CI: confidence interval; NA: not available.